426 related articles for article (PubMed ID: 34522598)
1. Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines.
Guo Y; Bera H; Shi C; Zhang L; Cun D; Yang M
Acta Pharm Sin B; 2021 Aug; 11(8):2565-2584. PubMed ID: 34522598
[TBL] [Abstract][Full Text] [Related]
2. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone palmitate large porous particles: A controlled release formulation for lung delivery of corticosteroids.
N'Guessan A; Fattal E; Chapron D; Gueutin C; Koffi A; Tsapis N
Eur J Pharm Sci; 2018 Feb; 113():185-192. PubMed ID: 28890202
[TBL] [Abstract][Full Text] [Related]
4. Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.
Okuda T; Okamoto H
Chem Pharm Bull (Tokyo); 2020; 68(7):589-602. PubMed ID: 32611996
[TBL] [Abstract][Full Text] [Related]
5. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
[TBL] [Abstract][Full Text] [Related]
6. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Albertson TE; Chenoweth JA; Pearson SJ; Murin S
Expert Opin Pharmacother; 2020 Feb; 21(2):213-231. PubMed ID: 31955671
[No Abstract] [Full Text] [Related]
7. Respiratory Tract: Structure and Attractions for Drug Delivery Using Dry Powder Inhalers.
ElKasabgy NA; Adel IM; Elmeligy MF
AAPS PharmSciTech; 2020 Aug; 21(7):238. PubMed ID: 32827062
[TBL] [Abstract][Full Text] [Related]
8. Long-acting inhaled medicines: Present and future.
Zhang C; D'Angelo D; Buttini F; Yang M
Adv Drug Deliv Rev; 2024 Jan; 204():115146. PubMed ID: 38040120
[TBL] [Abstract][Full Text] [Related]
9. Insulin inhalation--Pfizer/Nektar Therapeutics: HMR 4006, inhaled PEG-insulin--Nektar, PEGylated insulin--Nektar.
Drugs R D; 2004; 5(3):166-70. PubMed ID: 15139780
[TBL] [Abstract][Full Text] [Related]
10. Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis.
Sharma A; Vaghasiya K; Gupta P; Singh AK; Gupta UD; Verma RK
J Control Release; 2020 Aug; 324():17-33. PubMed ID: 32418903
[TBL] [Abstract][Full Text] [Related]
11. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
Van Holsbeke C; De Backer J; Vos W; Marshall J
Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
[TBL] [Abstract][Full Text] [Related]
12. Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs.
Patel B; Rashid J; Ahsan F
Eur J Pharm Sci; 2017 Jan; 96():560-570. PubMed ID: 27989858
[TBL] [Abstract][Full Text] [Related]
13. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
14. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
15. A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study.
Dumont EF; Oliver AJ; Ioannou C; Billiard J; Dennison J; van den Berg F; Yang S; Chandrasekaran V; Young GC; Lahiry A; Starbuck DC; Harrell AW; Georgiou A; Hopchet N; Gillies A; Baker SJ
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071044
[TBL] [Abstract][Full Text] [Related]
16. Enhanced pulmonary delivery of fluticasone propionate in rodents by mucus-penetrating nanoparticles.
Popov A; Schopf L; Bourassa J; Chen H
Int J Pharm; 2016 Apr; 502(1-2):188-97. PubMed ID: 26902722
[TBL] [Abstract][Full Text] [Related]
17. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
[TBL] [Abstract][Full Text] [Related]
18. Differences in Adherence Barriers to Inhaled Medicines between Japanese Patients with Chronic Obstructive Pulmonary Disease and Asthma Evaluated using the "Adherence Starts with Knowledge 20" (ASK-20) Questionnaire.
Toyama T; Kawayama T; Kinoshita T; Imamura Y; Yoshida M; Takahashi K; Fujii K; Higashimoto I; Hoshino T
Intern Med; 2019 Jan; 58(2):175-185. PubMed ID: 30210101
[TBL] [Abstract][Full Text] [Related]
19. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery.
Liu S; Watts AB; Du J; Bui A; Hengsawas S; Peters JI; Williams RO
Eur J Pharm Biopharm; 2015 Oct; 96():132-42. PubMed ID: 26220015
[TBL] [Abstract][Full Text] [Related]
20. Access to affordable medicines and diagnostic tests for asthma and COPD in sub Saharan Africa: the Ugandan perspective.
Kibirige D; Kampiire L; Atuhe D; Mwebaze R; Katagira W; Muttamba W; Nantanda R; Worodria W; Kirenga B
BMC Pulm Med; 2017 Dec; 17(1):179. PubMed ID: 29216852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
